Multiple trastuzumab biosimilars were approved and launched very quickly in the United States, which sets up an interesting scenario in the market to see the nuance of having multiple options available, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).
Multiple trastuzumab biosimilars were approved and launched very quickly in the United States, which sets up an interesting scenario in the market to see the nuance of having multiple options available, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).
Transcript
What patterns are you seeing in the use of trastuzumab biosimilars in patients with HER2-positive cancer?
We started this trastuzumab or HER2 inhibitor study to get a sense of what's happening out there—not having any real quantitative sense, in a broad sense, in a broad population about what's happening now that there are multiple biosimilars available. And we found that, at least in these early stages, trastuzumab is looking to be another one of the biosimilar success stories, at least in these early days, where there has been substantial uptake of biosimilars of one in particular—the first one that that came out—but we're seeing increasing numbers of all the biosimilars utilization. And I think that's positive.
And from a BBCIC perspective, we've been keeping track of what's happening with utilization with all of these products, but trastuzumab being new and being one that has multiple biosimilars, I think this story is only going to get more interesting, I think as the next couple of years go on, and we get to see more mature use of each of the products in the marketplace.
I think, you know, one of the interesting elements of looking across all of the HER2 inhibitors now that there are multiple biosimilars available is understanding what happens in the marketplace, and clinically, when you have, all of a sudden, lots of options. And it was kind of all of a sudden. There was a very short time period where they became available kind of all at once. And so, I think it's going to be very interesting to watch over the next few years how the nuances of having multiple options play out in the market.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More